280 related articles for article (PubMed ID: 19033369)
1. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
2. Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women.
Ng J; Chwalisz K; Carter DC; Klein CE
J Clin Endocrinol Metab; 2017 May; 102(5):1683-1691. PubMed ID: 28323948
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women.
Han S; Cho YS; Yoon SK; Lim KS; Cho SH; Kim J; Choe S; Jung J; Ghim JL; Choi S; Lee M; Kim SM; Kim HT; Lim HS; Yoon Shim J; Bae KS
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1111-e1120. PubMed ID: 33347565
[TBL] [Abstract][Full Text] [Related]
4. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
6. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
[TBL] [Abstract][Full Text] [Related]
7. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women.
Fraser GL; Ramael S; Hoveyda HR; Gheyle L; Combalbert J
J Clin Endocrinol Metab; 2016 Feb; 101(2):417-26. PubMed ID: 26653113
[TBL] [Abstract][Full Text] [Related]
8. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
[TBL] [Abstract][Full Text] [Related]
9. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of elagolix in the treatment of endometriosis.
Perricos A; Wenzl R
Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women.
Chen MJ; Marroum P; Chiu YL; Neenan M; Mostafa NM; Shebley M
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):601-610. PubMed ID: 38593267
[TBL] [Abstract][Full Text] [Related]
12. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
14. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
[TBL] [Abstract][Full Text] [Related]
16. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
17. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
18. Oral GnRH Antagonist Ovarian Suppression After Escape From GnRH Agonist in Breast Cancer Patients.
Coyne K; Silverman P; Liu JH
Clin Breast Cancer; 2020 Oct; 20(5):e551-e554. PubMed ID: 32616435
[No Abstract] [Full Text] [Related]
19. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
20. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902).
Struthers RS; Chen T; Campbell B; Jimenez R; Pan H; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2006 Oct; 91(10):3903-7. PubMed ID: 16849403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
